Pfizer working on the hypothesis of annual coronavirus vaccination. This was stated by Albert Bourla, president and CEO of Pfizer, in a note in which the US pharmaceutical group and its German partner detail the new supply agreement signed with the European Union for 1.8 billion doses in the period 2021-23 . “Continuing vaccination” against pandemic coronavirus “beyond 2021 is essential as Covid-19 continues to spread rapidly throughout Europe and the world. After more than a year” since the beginning of the emergency “we continue to improve knowledge of Covid -19 and we are working to understand if, similar to what happens with seasonal flu, annual vaccination can provide the most lasting protection “against Sars-CoV-2, explains Bourla. “We are proud to be a long-term partner in the EU’s battle against this devastating pandemic – adds the CEO – and to remain firm in our commitment to produce and supply potentially billions more doses of our vaccine every year”. There is growing evidence that Covid-19 will continue to pose a public health challenge for years – emphasizes Ugur Sahin, co-founder and CEO of BioNTech – This contract with the European Commission will ensure that sufficient doses of Comirnaty are available for all EU citizens also in 2022 and 2023. With these additional doses and our continued investment in research and development, aimed at adapting our vaccine to address new and emerging variants “of Sars-CoV-2,” we will continue to have an impact significant in the EU’s efforts to protect public health “.” Based on current projections, Pfizer and BioNTech believe they can produce at least 2.5 billion of doses of the vaccine “Comirnaty against Covid 19” in total by the end of 2021, with the potential to provide up to 3 billion doses “globally, underline the US pharmaceutical group and its German partner in the note. The 900 million covered by the new contract will be disbursed on a monthly basis starting from next December and the supply will continue until 2023. Also considering the option of an additional 900 million doses, the supply of vaccine therefore rises to 2.4 billion doses. anti-Covid to the European Union by 2023. All doses for Ce should be produced in the European Union, the two companies specify.